Drug Price Transparency Act
Bill journey · stage 2 of 5
Under committee review
What it doesSummary introduced in house (Sep 27, 2018)
Drug Price Transparency Act
This bill requires the Centers for Medicare & Medicaid Services to report on the feasibility of basing payment rates for prescription drugs under Medicare and Medicare Advantage on the average price of such drugs in countries that are members of the Organization for Economic Cooperation and Development (an intergovernmental organization focused on global economic development).
What just happenedOct 10, 2018
Referred to the Subcommittee on Health.
Who’s behind it
- Introduced in HouseSep 27, 2018
- Oct 10, 2018Committee
Referred to the Subcommittee on Health.
Health Subcommittee - Sep 27, 2018IntroReferralH11100
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Ways and Means Committee - Sep 27, 2018IntroReferralH11100
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Energy and Commerce Committee - Sep 27, 2018IntroReferralIntro-H
Introduced in House
- Sep 27, 2018IntroReferral1000
Introduced in House